期刊文献+

慢性心力衰竭患者血浆尾加压素Ⅱ及肾上腺髓质素的变化 被引量:9

The changes of plasma urotensin Ⅱ and adrenomedullin in patients with chronic heart failure
下载PDF
导出
摘要 目的研究慢性心力衰竭患者血浆尾加压素Ⅱ(urotensinⅡ,UⅡ)、肾上腺髓质素(adrenomedullin,ADM)浓度的变化并探讨其临床意义。方法测定90例心力衰竭患者(心力衰竭组)治疗前后血浆UⅡ、ADM浓度及左心室射血分数(left ventricular ejection fraction,LVEF)、左心室质量指数(left ventricular mass index,LVMI)变化,进行相关分析,并与60名健康人(对照组)对照。结果心力衰竭组血浆ADM、UⅡ浓度均显著高于对照组,差异有统计学意义[(38.22±8.28)ng/L比(17.58±3.43)ng/L,P<0.01;(3.29±0.92)pmol/L比(1.85±0.45)pmol/L,P<0.01];心力衰竭组血浆UⅡ浓度与心功能级别正相关(r=0.765,P<0.01),与LVEF负相关(r=-0.681,P<0.01),与LVMI正相关(r=0.705,P<0.01),与血浆ADM浓度正相关(r=0.718,P<0.01);心力衰竭患者治疗后血浆ADM、UⅡ浓度比治疗前显著降低,差异有统计学意义[(29.61±6.88)ng/L比(38.31±8.11)ng/L,P<0.01;(2.52±0.49)pmol/L比(3.43±1.02)pmol/L,P<0.01]。结论血浆ADM和UⅡ浓度随心力衰竭加重而升高,UⅡ、ADM共同参与了心力衰竭的病理生理过程;血浆UⅡ浓度可作为判断心力衰竭严重程度和临床评价心力衰竭治疗效果的生物学指标。 Objectives To observe the changes of the concentration of urotensin Ⅱ ( U Ⅱ ) , adrenomedullin (ADM) in plasma in patients with chronic heart failure (CHF) and their clinical implications. Methods The concentration of U Ⅱ , ADM in plasma and the left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI) of 90 patients with CHF (CHF group) and 60 healthy subjects (control group) were measured and analyzed. Results The concentration of U Ⅱ , ADM in plasma were significantly higher in the CHF group than in the eontrolgroup [(38.22±8.28) ng/Lvs. (17.58±3.43) ng/L, P〈0.01; (3.29±0.92) pmol/Lvs. (1.85±0.45) pmol/L, P〈0.01 ] ; The levels of plasma U Ⅱ and ADM increased parallel with the severity of heart failure ; The concentration of U Ⅱ in plasma negatively correlated with LVEF, and positively correlated with LVMI and ADM; Compared before and after treatment, there were significant differences in CHF patients with ADM and U Ⅱ [ (29.61±6.88) ng/L vs. (38.31±8.11) ng/L, P〈0.01; (2.52±0.49) pmol/Lvs. (3.43±1.02) pmol/L, P〈0.01]. Conclusions The concentration of U Ⅱ , ADM in plasma increased with the severity of heart failure. U Ⅱ , ADM fellowship CHF pathology physiological process. The concentration of U Ⅱ in plasma in CHF patients may serve as an index of the severity of CHF and the assessment for treatment effect.
出处 《岭南心血管病杂志》 2009年第3期191-194,共4页 South China Journal of Cardiovascular Diseases
关键词 心力衰竭 尾加压素Ⅱ 肾上腺髓质素 冠状动脉疾病 heart failure urotensin Ⅱ adrenomedullin coronary artery disease
  • 相关文献

参考文献12

  • 1陈灏珠.内科学[M] 第4版[M].北京:人民卫生出版社,1998.616.
  • 2Braunwald.陈淑珠主译.心脏病学[M].第5版.北京:人民卫生出版社,2001:153-154.
  • 3PERTICONE F,MAIO R,CERAVOLO R,et al.Relationship between left ventricular mass and endotheliamdependent vasedilation in never-treated hypertensive patients[J].Circulation,1999,99 (15):1991-1996.
  • 4CHEUNG B M,LEUNG R,MAN Y B,et al.Plasma concentration of urotensin Ⅱ is raised in hypetension[J].J Hypertens,2004,22 (7):1341-1344.
  • 5TZANIDIS A,HANNAN R D,THOMAS W G,et al.Direct actions of urotensin Ⅱ on the heart:implications for cardiac fibrosis and hypertrophy[J].Circ Res,2003,93 (3):246-253.
  • 6石向东,李志梁,吴宏超,吕永恒,王同汉,傅强,徐春生,唐朝枢.尾加压素Ⅱ促血管内皮细胞分泌肾上腺髓质素的作用[J].中华心血管病杂志,2005,33(9):836-839. 被引量:12
  • 7LAPP H,BOERRIGTER G,COSTELLO-BOERRIGTER L C,et al.Elevated plasma haman uroteasin-Ⅱ-like immunoreactivity in ischemic cardiomyopathy[J].Int J Cardiol,2004,94 (1):93-97.
  • 8ZHANG Y,LI J,CAO J,et al.Effect of chronic hypoxia on contents of urotensin Ⅱ and its functional receptors in rat myocardium[J].Heart Vessels,2002,16 (2):64-68.
  • 9RUSSELL F D,MOLENAAR P,O'BRIEN D M.Cardiostimulant effects of urotensin-Ⅱ in human heart in vitro[J].Br J Pharmacol,2001,132 (1):5-9.
  • 10TSURUDA T,BURNETT J C J R,Adrenomedullin:an autocrine/paracrine factor for eardiorenal protection[J].Circ Res,2002,90 (6):625-627.

二级参考文献16

  • 1Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinalcord. Proc Natl Acad Sci U S A, 1998,95:15803-15808.
  • 2Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999,401:282-286.
  • 3Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell proliferation. J Hypertens,2001,19 :2191-2196.
  • 4Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 2001,104:16-18.
  • 5Kitamural K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.Biochem Biophys Res Commun, 1993,192:552-560.
  • 6Bern HA, Pearson D, Larson BA, et al. Neurohormones from fish tails: the caudal neurosecretory system. Ⅰ. "Urophysiology" and the caudal neuroseeretory system of fishes. Recent Prog Horm Res, 1985,41:533-552.
  • 7Douglas SA, Ohlstein EH. Human urotension Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular diease. Trends Cardiovasc Med, 2000, 10:229-237.
  • 8Hayakaawa H, Hirata Y, Kakoki M, et al. Role of nitricoxide-cGMP pathway in adrenomedullin induced vasodilation in the rat.Hypertension, 1999, 33 : 689-693.
  • 9Tsuruda T, Kato J, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension,1998,31 ( 1 Pt 2) :505-510.
  • 10Chini EN, Chini CC, Bolliger C, et al. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int, 1997,52:917-925.

共引文献31

同被引文献48

引证文献9

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部